Doctor Adam Cooper
Senior Lecturer in Medical Oncology,
School of Medicine
Biography
Qualifications
- MBBS University of Queensland
- BSc University of Sydney
Organisational Unit (School / Division)
- School of Medicine
Contact
| Email: | Adam.Cooper@westernsydney.edu.au |
|---|---|
| Phone: | |
| Mobile: | |
| Location: | Campbelltown |
PLEASE NOTE: obtaining information from this Directory must be for the legitimate purposes of doing business with and within Western Sydney University, and must not be used for unsolicited bulk e-mailing (spamming) or similar purposes.
Publications
Chapters in Books
- Po, J., Ma, Y., Luk, A., Lynch, D., Balakrishnar, B., Brungs, D., Azimi, F., Cooper, A., Saricilar, E., Murthy, V., Souza, P. and Becker, T. (2021), 'Single-cell analysis of BRAFV600E and NRASQ61R mutation status in melanoma cell lines as method generation for circulating melanoma cells', Melanoma: Methods and Protocols, Humana Press 9781071612040.
- Po, J., Ma, Y., Balakrishnar, B., Brungs, D., Azimi, F., Cooper, A., Saricilar, E., Murthy, V., Souza, P. and Becker, T. (2021), 'PD-L1 detection on circulating melanoma cells', Melanoma: Methods and Protocols, Humana Press 9781071612040.
Journal Articles
- Nindra, U., Childs, S., Yoon, R., Haider, S., Hong, M., Roohullah, A., Cooper, A., Wilkinson, K., Pal, A. and Chua, W. (2024), '[In Press] Survival outcomes in older adults undergoing early phase clinical trials', Journal of Geriatric Oncology, .
- Gao, B., Voskoboynik, M., Cooper, A., Wilkinson, K., Hoon, S., Hsieh, C., Cai, S., Tian, Y., Bao, J., Ma, N., Wang, C., Zhang, M., Li, B., Guo, M., Zhou, R., Wang, X., Xu, C. and Souza, P. (2023), 'A phase 1 dose-escalation study of the poly(ADP-ribose) polymerase inhibitor senaparib in Australian patients with advanced solid tumors', Cancer, vol 129, no 7 , pp 1041 - 1050.
- Tune, B., Sareen, H., Powter, B., Kahana-Edwin, S., Cooper, A., Koh, E., Lee, C., Po, J., McCowage, G., Dexter, M., Cain, L., O?Neill, G., Prior, V., Karpelowsky, J., Tsoli, M., Baumbusch, L., Ziegler, D., Roberts, T., Souza, P., Becker, T. and Ma, Y. (2023), 'From pediatric to adult brain cancer : exploring histone H3 mutations in Australian brain cancer patients', Biomedicines, vol 11, no 11 .
- Nindra, U., Shivasabesan, G., Childs, S., Yoon, R., Haider, S., Hong, M., Cooper, A., Roohullah, A., Wilkinson, K., Pal, A. and Chua, W. (2023), 'Time toxicity associated with early phase clinical trial participation', ESMO Open, vol 8, no 6 .
- Zheng, Y., Mislang, A., Coward, J., Cosman, R., Cooper, A., Underhill, C., Zhu, J., Xiong, J., Jiang, O., Wang, H., Xie, Y., Zhou, Y., Jin, X., Li, B., Wang, Z., Kwek, K., Xia, D., Xia, Y. and Xu, N. (2022), 'Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers', Cancer Immunology, Immunotherapy, vol 71, no 10 , pp 2371 - 2379.
- Powter, B., Jeffreys, S., Sareen, H., Cooper, A., Brungs, D., Po, J., Roberts, T., Koh, E., Scott, K., Sajinovic, M., Vessey, J., Souza, P. and Becker, T. (2021), 'Human TERT promoter mutations as a prognostic biomarker in glioma', Journal of Cancer Research and Clinical Oncology, vol 147, no 4 , pp 1007 - 1017.
- Scott, K., Mann, T., Fatima, S., Sajinovic, M., Razdan, A., Kim, R., Cooper, A., Roohullah, A., Bryant, K., Kanapaddala Gamage, K., Harman, D., Vafaee, F., Graham, G., Church, W., Russell, P., Dong, Q. and Souza, P. (2021), 'Human Group IIA Phospholipase A2 : three decades on from its discovery', Molecules, vol 26, no 23 .
- Lynch, D., Powter, B., Po, J., Cooper, A., Garrett, C., Koh, E., Sheridan, M., Van Gelder, J., Darwish, B., Mckechnie, S., Bazina, R., Jaeger, M., Roberts, T., Souza, P. and Becker, T. (2020), 'Isolation of circulating tumor cells from glioblastoma patients by direct immunomagnetic targeting', Applied Sciences, vol 10, no 9 .
- Sareen, H., Garrett, C., Lynch, D., Powter, B., Brungs, D., Cooper, A., Po, J., Koh, E., Vessey, J., Mckechnie, S., Bazina, R., Sheridan, M., Van Gelder, J., Darwish, B., Jaeger, M., Roberts, T., Souza, P. and Becker, T. (2020), 'The role of liquid biopsies in detecting molecular tumor biomarkers in brain cancer patients', Cancers, vol 12, no 7 .
- Nimir, M., Ma, Y., Je?reys, S., Opperman, T., Young, F., Khan, T., Ding, P., Chua, W., Balakrishnar, B., Cooper, A., Souza, P. and Becker, T. (2019), 'Detection of AR-V7 in liquid biopsies of castrate resistant prostate cancer patients : a comparison of AR-V7 analysis in circulating tumor cells, circulating tumor RNA and exosomes', Cells, vol 8, no 7 .
- Panizza, B., Souza, P., Cooper, A., Roohullah, A., Karapetis, C. and Lickliter, J. (2019), 'Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46)', EBioMedicine, vol 50 , pp 433 - 441.
- Aghajani, M., Cooper, A., McGuire, H., Jeffries, T., Saab, J., Ismail, K., Souza, P., Bray, V., De Saint Groth, F., Niles, N. and Roberts, T. (2019), 'Pembrolizumab for anaplastic thyroid cancer : a case study', Cancer Immunology, Immunotherapy, vol 68 , pp 1921 - 1934.
- Harris, B., Walsh, J., Neciunaite, R., Manders, P., Cooper, A. and de Souza, P. (2018), 'Ring a ring o'roses, a patient with Kaposi's? : pazopanib, pazopanib, it might go away : Mediterranean (classic) Kaposi sarcoma responds to the tyrosine kinase inhibitor pazopanib after multiple lines of standard therapy', Clinical and Experimental Dermatology, vol 43, no 2 , pp 234 - 236.
- Roohullah, A., Cooper, A., Lomax, A., Aung, J., Barge, A., Chow, L., McHale, M., Desai, J., Whittle, J., Tran, B., de Souza, P. and Horvath, L. (2018), 'A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers', Investigational New Drugs, vol 36, no 5 , pp 886 - 894.
- Vilain, R., Menzies, A., Wilmott, J., Kakavand, H., Madore, J., Guminski, A., Liniker, E., Kong, B., Cooper, A., Howle, J., Saw, R., Jakrot, V., Lo, S., Thompson, J., Carlino, M., Kefford, R., Long, G. and Scolyer, R. (2017), 'Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in melanoma', Clinical Cancer Research, vol 23, no 17 , pp 5024 - 5033.
- Liniker, E., Menzies, A., Kong, B., Cooper, A., Ramanujam, S., Lo, S., Kefford, R., Fogarty, G., Guminski, A., Wang, T., Carlino, M., Hong, A. and Long, G. (2016), 'Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma', OncoImmunology, vol 5, no 9 .